news

GlobalData forecasts huge increase in psoriasis therapeutics market

0
SHARES

The psoriasis therapeutics market is set to more than double from $6.6 billion in 2014 to over $13.3 billion by 2024, according to research and consulting firm, GlobalData.

Psoriasis therapeutics market set to increase

This significant increase represents an annual growth rate of 7.3% – an encouraging statistic for the 2-3% of sufferers throughout the world who are looking for relief from the chronic genetic skin disorder.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Psoriasis therapeutics market driven by many factors

GlobalData’s report states that this impressive growth will be driven by the launch of new psoriasis products, as well as the expansion of existing therapies – such as dimethyl fumarate from Germany into the US and major European markets – and the rapid uptake of biosimilars for currently marketed biologics.  The patents for high-grossing branded drugs, such as TNF inhibitors, Humira, Enbrel and Remicade, in the US and 5EU in France, Germany, Italy, Spain and the UK are due to expire over the forecast period and will inevitably spread growth throughout the different levels of products in the coming years.

Unique drugs will enhance psoriasis therapeutics market

Although the psoriasis market will be crowded, novel products from Eli Lilly and Johnson & Johnson are expected to achieve sales in excess of $1 billion each due to their high clinical efficacy and safety profiles

Nikhilesh Sanyal, Ph.D., GlobalData’s Analyst covering Immunology, explains: “Although the psoriasis market will be crowded, novel products such as Eli Lilly’s anti-interleukin(IL)-17 drug, ixekizumab, and Johnson & Johnson’s (J&J’s) IL-23 inhibitor, guselkumab, are expected to achieve sales in excess of $1 billion each by the end of the forecast period, primarily due to their high clinical efficacy and safety profiles.”

“Other pipeline therapies with exceptional efficacy and safety credentials include Merck’s tildrakizumab and AstraZeneca/Valeant’s brodalumab, which will go a long way towards addressing the current need for therapies that can provide long-lasting results without side effects or an increased risk of comorbidities.”

More information about the report can be found here: http://store.globaldata.com

Related organisations

Related diseases & conditions

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Share via